---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009485"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:42:18.152628+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma reports FY2022 net loss $34.7M; neffy NDA under FDA review, PDUFA mid-2023

## Summary
- Net loss of $14.4M for Q4 2022 and $34.7M for full year 2022; cash & investments $274.4M as of Dec 31, 2022.
- NDA for neffy (intranasal epinephrine) accepted by FDA; PDUFA target action date anticipated in mid-2023.
- MAA for neffy also under review by EMA; company reacquired European rights.
- R&D expenses $4.7M (Q4) and $18.4M (FY); G&A $10.7M (Q4) and $18.5M (FY).
- Cash runway sufficient for at least three years; preparing for potential U.S. launch in 2023 if approved.

## SEC filing metadata
- accession: 0000950170-23-009485
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/0000950170-23-009485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/sbtx-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009485
- JSON: https://secwatch.observer/filing/0000950170-23-009485.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009485.txt

## Key facts
- Earnings Releases
  ARS Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income $34.7 million.
  - Period: the year ended December 31, 2022
  - Net income: $34.7 million
  - Result: reported results
  source text: Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/0000950170-23-009485-index.htm
- Earnings Releases
  ARS Pharmaceuticals, Inc. reported the quarter ended December 31, 2022 results: net income $14.4 million.
  - Period: the quarter ended December 31, 2022
  - Net income: $14.4 million
  - Result: reported results
  source text: Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/0000950170-23-009485-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.